Neuroinflammation is linked to a host of detrimental brain disorders, including Alzheimer's and Parkinson's disease. A collaborative research team from Houston Methodist and Rice University has developed a way to fight back with a tiny, …

Eli Lilly and Company announced that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease (AD), in adults with mild cognitive impairment as well as those …

The European Union on Thursday approved the highly contentious Alzheimer's medication Kisunla under strict conditions, with the drug's effectiveness hotly debated by the medical community. "The European Commission has granted EU marketing …

A newly-approved Alzheimer's drug could help tens of thousands of Australians with the condition, but most people won't have access to the "incredibly important" medicine. Lacenamab, which has the brand name Leqembi, has been approved by …

A key protein in the brain could reveal if someone is likely to develop Alzheimer's disease later in life, a new study has revealed.  Researchers from Florida International University investigated the role of TSPO, a protein that serves as a biomarker …

Investigation of cellular processes that cause neurodegeneration in spider, rodent and human brain with focus on Alzheimer Disease Vermont Business Magazine According to current estimates, worldwide over 50 million people are affected by irreversible …

President Trump wants to make America's drug pricing system more like Europe's. But in the process, he risks unintentionally cutting off Americans' access to lifesaving medicines. The Most Favored Nation (MFN) proposal would tie US drug prices …

20 abstracts presented across World Sleep and Psych Congresses showcase Jazz's leadership in sleep medicine Novel results from the Phase 4 DUET trial underscore the significance of appropriate treatment options in adults with narcolepsy or idiopathic …

Newswise — New York, NY [September 25, 2025] — A new study led by the Icahn School of Medicine at Mount Sinai offers one of the most comprehensive views yet of how brain cells interact in Alzheimer’s disease, mapping protein networks that reveal …

Coverage of aging is supported in part by AARP Arizona People living with a form of Lewy body dementia potentially have access to a promising investigational drug that appears to reduce or improve symptoms. Dr. Dave Shprecher is a movement disorder …